.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Citi
Baxter
QuintilesIMS
UBS
Fish and Richardson
Julphar
Chubb
Deloitte
McKesson

Generated: July 22, 2017

DrugPatentWatch Database Preview

PROGRAF Drug Profile

« Back to Dashboard

Which patents cover Prograf, and when can generic versions of Prograf launch?

Prograf is a drug marketed by Astellas and is included in two NDAs.

The generic ingredient in PROGRAF is tacrolimus. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.

Summary for Tradename: PROGRAF

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list4
Bulk Api Vendors: see list79
Clinical Trials: see list155
Patent Applications: see list6,037
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PROGRAF at DailyMed

Pharmacology for Tradename: PROGRAF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
PROGRAF
tacrolimus
CAPSULE;ORAL050708-003Aug 24, 1998ABRXYesNo► Subscribe► Subscribe
Astellas
PROGRAF
tacrolimus
INJECTABLE;INJECTION050709-001Apr 8, 1994RXYesYes► Subscribe► Subscribe
Astellas
PROGRAF
tacrolimus
CAPSULE;ORAL050708-001Apr 8, 1994ABRXYesNo► Subscribe► Subscribe
Astellas
PROGRAF
tacrolimus
CAPSULE;ORAL050708-002Apr 8, 1994ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PROGRAF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas
PROGRAF
tacrolimus
INJECTABLE;INJECTION050709-001Apr 8, 19945,260,301► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Novartis
McKesson
Healthtrust
McKinsey
Daiichi Sankyo
Farmers Insurance
Baxter
Fuji
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot